Aurinia Pharmaceuticals Inc.
Company & revenue
About Aurinia Pharmaceuticals Inc.
Who they are
Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis.
Detailed revenue, brand and relationship research has not yet been completed for AUPH.
Wall Street Score
Overall investment score · Quality, value, risk and opportunity
84
Strong
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
84
Strong
Financial Strength
80
Business Quality / Moat
99
Management
100
Growth Quality
63
Risk / Durability
55
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
79
Fair
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
77/100
Building Historical Record
Model Score 77/100 — estimates relative performance potential, distinct from WallStreetScore (company quality).
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
WSS currently rates the company as financially and fundamentally strong.
At today’s price, the WSS valuation framework currently reads as relatively attractive.
The model outlook is currently positive.
- •Strong overall Company Strength score
- •Balance-sheet / debt profile scores strongly
- •Valuation scores attractively
- •Recent buyback activity is present
No material warning is currently being highlighted from the available summary data.
Company-specific research
Questions worth answering for AUPH
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
- •Can AUPH maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
- •Is AUPH's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
- •How is AUPH likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
- •Is AUPH's valuation discount tied to a temporary concern or to a longer-term business risk?
Essential Investment Snapshot
Wall Street Score
84
Opportunity Score
79
Market Cap
$2.04B
P/E Ratio
6.9
EPS
$2.36
52-Week High
$19.25
52-Week Low
$10.90
Beta
1.41
Intrinsic Value
$90.86
Analyst Target
$16.00
Shares Outstanding
138.7M
Total Revenue
$311.5M
Total Debt
$60.4M
Dividend
No current dividend
Liquidation Value / Share
$4.43
Momentum & Volatility Signals
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
Weakening momentum
Low movement
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for AUPH
Detected from reported data — verify before acting.Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
Community Sentiment
0 active · 0 total callsNo personal call yet on AUPH.
What the Bulls Say
- +Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
- +Product opportunity: Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurini.
- +Positive free cash flow may provide capacity to invest in growth.
What the Bears Say
- −Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Biotechnology industry.
Bull and bear cases summarize disclosed catalysts, growth opportunities and risks; they are not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdownWas this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
Score Changes
6 historical score records availablePrevious Score
84
Sep 9, 2026
Change
Unchanged
Current Score
84
Oct 1, 2026
Category Changes
AUPH score was unchanged.
Projected Score
Projected Score
91
Projected Change
+6.2%
Preliminary comparable-period financial changes suggest improvement of approximately 6.2 points. This is a projected estimate, not the official WallStreetScore.
Price vs. Value
UndervaluedCurrent Price
$15.83
Intrinsic Value
$90.86
Difference
−$75.03
-82.6% vs IV
Margin of Safety
82.6%
Related Companies
BiotechnologyNews
Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises
Aurinia Pharmaceuticals and Teva Settle Patent Dispute for Kidney Disease Drug
Aurinia Settles Patent Litigation with Teva
Aurinia Pharmaceuticals Doubles Down On Its Pipeline
Related Stock Research
Continue researching this company with related Wall Street Score rankings and investing guides.
Score Alerts
Premium unlocks alerts when a score rises, falls, or reaches your target price.
Start 7-Day Free TrialPortfolio Score
Premium unlocks portfolio scoring, strongest and weakest holdings, and overall margin of safety.
Start 7-Day Free Trial